Compare Sterling Biotech with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs JUBILANT LIFE SCIENCES - Comparison Results

STERLING BIOTECH     Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH JUBILANT LIFE SCIENCES STERLING BIOTECH/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x -0.4 15.2 - View Chart
P/BV x 0.0 1.8 0.8% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 STERLING BIOTECH   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
JUBILANT LIFE SCIENCES
Mar-19
STERLING BIOTECH/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs11898 1.2%   
Low Rs3618 0.6%   
Sales per share (Unadj.) Rs26.8572.0 4.7%  
Earnings per share (Unadj.) Rs-15.036.2 -41.3%  
Cash flow per share (Unadj.) Rs-5.559.5 -9.2%  
Dividends per share (Unadj.) Rs04.50 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs54.9301.9 18.2%  
Shares outstanding (eoy) m267.87159.28 168.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.3 19.6%   
Avg P/E ratio x-0.520.9 -2.2%  
P/CF ratio (eoy) x-1.312.7 -10.0%  
Price / Book Value ratio x0.12.5 5.0%  
Dividend payout %012.4 0.0%   
Avg Mkt Cap Rs m1,862120,694 1.5%   
No. of employees `0001.42.4 56.7%   
Total wages/salary Rs m54719,260 2.8%   
Avg. sales/employee Rs Th5,303.338,120.6 13.9%   
Avg. wages/employee Rs Th403.88,058.4 5.0%   
Avg. net profit/employee Rs Th-2,959.02,414.3 -122.6%   
INCOME DATA
Net Sales Rs m7,18191,108 7.9%  
Other income Rs m43357 11.9%   
Total revenues Rs m7,22391,466 7.9%   
Gross profit Rs m94717,390 5.4%  
Depreciation Rs m2,5433,709 68.6%   
Interest Rs m4,3772,198 199.1%   
Profit before tax Rs m-5,93111,840 -50.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m-1,9243,268 -58.9%   
Profit after tax Rs m-4,0075,770 -69.4%  
Gross profit margin %13.219.1 69.1%  
Effective tax rate %32.427.6 117.6%   
Net profit margin %-55.86.3 -881.0%  
BALANCE SHEET DATA
Current assets Rs m14,33545,848 31.3%   
Current liabilities Rs m49,80920,897 238.4%   
Net working cap to sales %-494.027.4 -1,803.9%  
Current ratio x0.32.2 13.1%  
Inventory Days Days40357 710.3%  
Debtors Days Days17151 335.0%  
Net fixed assets Rs m55,43265,498 84.6%   
Share capital Rs m268159 168.2%   
"Free" reserves Rs m13,93547,930 29.1%   
Net worth Rs m14,70148,089 30.6%   
Long term debt Rs m9,47842,429 22.3%   
Total assets Rs m73,988114,685 64.5%  
Interest coverage x-0.46.4 -5.6%   
Debt to equity ratio x0.60.9 73.1%  
Sales to assets ratio x0.10.8 12.2%   
Return on assets %0.56.9 7.2%  
Return on equity %-27.312.0 -227.1%  
Return on capital %-6.412.4 -51.8%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,86012,422 15.0%   
Fx outflow Rs m2517,227 0.1%   
Net fx Rs m1,835-4,805 -38.2%   
CASH FLOW
From Operations Rs m1,71911,215 15.3%  
From Investments Rs m-3,148-10,118 31.1%  
From Financial Activity Rs m1,4266,574 21.7%  
Net Cashflow Rs m-37,612 -0.0%  

Share Holding

Indian Promoters % 33.9 45.6 74.3%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 0.0 8.7 -  
FIIs % 9.9 21.2 46.7%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 21.1 186.3%  
Shareholders   21,482 23,815 90.2%  
Pledged promoter(s) holding % 55.9 15.9 352.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   ALEMBIC LTD  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  SUN PHARMA  

Compare STERLING BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY19); Net Profit Up 25.7% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 25.7% YoY). Sales on the other hand came in at Rs 24 bn (up 15.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH - PANACEA BIOTECH COMPARISON

COMPARE STERLING BIOTECH WITH

MARKET STATS